JNJ 10198409

Key Product Details

Product Description

JNJ 10198409 is a potent platelet-derived growth factor receptor (PDGFR) inhibitor (IC₅₀ values are 4.2 and 45 nM for PDGFRβ and PDGFRα, respectively). Also inhibits c-Abl, Lck, c-Src and Fyn kinases (IC₅₀ values are 22, 100, 185 and 378 nM respectively). Displays antiproliferative activity in multiple tumor cell lines. Accelerates down regulation of fibroblast genes in transdifferentiation of human fibroblasts into functional cardiomyocytes, within 9C cocktail.

For more information about how JNJ 10198409 may be used, see our protocol: Converting Fibroblasts into Cardiomyocytes (9C Cocktail)

Licensing Information

Sold with the permission of Janssen Pharmaceutica N.V.

Product Specifications for JNJ 10198409

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JNJ 10198409

The following data is based on the product molecular weight 325.34.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.07 mL	15.37 mL	30.74 mL
5 mM	0.61 mL	3.07 mL	6.15 mL
10 mM	0.31 mL	1.54 mL	3.07 mL
50 mM	0.06 mL	0.31 mL	0.61 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 45 publications citing the usage of this product.

• Cao Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016 PMID: 27127239
• Ho (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J.Med.Chem. 2005 PMID: 16366598

Product Documents for JNJ 10198409